Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
By Editor_wr On Apr 10, 2025
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria.
This agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region. Rucaparib, marketed as Rubraca®, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an important treatment option for patients battling ovarian cancer, the 8th most common cancer in women globally[1], and prostate cancer, the 4th most common cancer worldwide and the second most common cancer in men[2].
Rucaparib has received regulatory approval from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (U.S. FDA).
Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: 'We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA. This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day.'
As the company's first innovative small-molecule oral therapy in oncology approved by both the U.S. FDA and EMA, this partnership strengthens Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes.
[1] Ovarian cancer statistics | World Cancer Research Fund
[2] Prostate cancer statistics | World Cancer Research Fund
Comments are closed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
9 hours ago
- Web Release
Tealium expands Middle East investment to power real-time AI data strategies for AI success
Tealium, the leading intelligent real-time data streaming platform, hosted its regional event, 'AI Meets ROI: Customer Data Strategies to Accelerate Growth,' in Dubai. The gathering united government stakeholders, enterprise leaders, and digital innovators to examine how high-quality, real-time customer data can drive business results from AI investments. With regional digital transformation accelerating, the event explored how organizations can translate AI experimentation into sustainable growth, operational efficiency, and personalized customer experiences. The event featured a keynote from Ali Behnam, Co-Founder of Tealium and Guillaume Thfoin, Chief Data Officer at Schneider Electric, who shared practical guidance on building enterprise-wide AI programs. This comes at a pivotal time, with AI's contribution to Middle Eastern economies expected to grow from 20% to 34% by 2030, underscoring the region's rapid digital acceleration. 'We are proud to invest in the UAE, not just by expanding our presence, but by enabling enterprises to thrive in the age of AI, responsibly and in full alignment with local data governance,' said Ali Behnam, Co-Founder of Tealium. 'AI is only as effective as the data that powers it, and we're here to help businesses activate their data with trust and precision. Our latest research shows that 81% of CDP users gain a competitive edge in AI initiatives, underlining the need for a real-time, consented data foundation.' Tealium has been recognized as a Leader in the Gartner® Magic Quadrant™ for Customer Data Platforms for two consecutive years, a testament to its innovation, scalability, and global impact. It's also one of the first platforms to integrate with MCP, the industry-standard framework built by Anthropic. The company's AI Innovation strategy helps organizations overcome core challenges in AI adoption, from fragmented data systems to compliance risk. Its platform prepares, transforms, and labels customer data in real-time, ensuring it is AI-ready and compliant before it ever reaches a model. With 42% of companies in the UAE alone already leveraging AI in their business operations, companies face mounting pressure to deliver measurable value from their AI efforts. Tealium's localized offering supports this by allowing regional brands to activate AI insights across their digital ecosystems without additional data fees, accelerating time-to-value while staying compliant. By integrating AI models directly into customer engagement touchpoints, Tealium enables businesses to operationalize insights instantly. Real-time activation engines allow for AI-generated recommendations to be delivered at scale across marketing, commerce, and service platforms. With 84% of Tealium users stating that a CDP makes AI projects easier, the company's focus is to simplify, connect, and activate data in real-time so organizations can realize ROI from AI, faster and with greater confidence. Aligned with its broader investment in the Middle East, Tealium will enable data residency capabilities on AWS data centers in the UAE, ensuring customers benefit from localized data storage, improved latency, and strict compliance with data governance frameworks. Tealium has been locally established in the Middle East since 2018, with regional operations headquartered in Dubai and managed by Shadi Hatoum, Sales Director for MEA. Since then, Tealium has expanded its footprint across key markets including the UAE, Saudi Arabia, Qatar, and Turkey, supporting leading enterprises in unifying customer data and driving real-time personalization at scale. The company remains focused on forging strong regional partnerships and supporting both public and private sector organizations as they advance their data and AI capabilities.
TECHx
a day ago
- TECHx
AmiViz Ranked Among Top Tech Workplaces in GCC
Home » Tech Value Chain » Distributors » AmiViz Ranked Among Top Tech Workplaces in GCC AmiViz, a cybersecurity-focused value-added distributor based in the Middle East, has been ranked 22nd on the 2025 list of Best Workplaces in Technology in the GCC region. The ranking was announced by Great Place to Work®, a global authority on workplace culture. This recognition highlights AmiViz's strong commitment to creating an inclusive, empowering, and innovation-driven work environment. It reflects the company's efforts to foster a culture where trust, collaboration, and professional growth are a priority. According to Great Place to Work®, the ranking is based on employee feedback collected through confidential surveys. It also includes an in-depth assessment of the company's HR practices, leadership involvement, and focus on employee well-being. AmiViz stood out for promoting a transparent and agile workplace. The company was recognized for encouraging employees to excel and contribute meaningfully to its mission. The company reported that its people-centric approach remains a core value. It continues to invest in employee development and well-being while navigating a rapidly evolving tech landscape. AmiViz promotes continuous learning and upskilling The company values diversity and encourages innovation Ilyas Mohammed, Chief Operating Officer at AmiViz, expressed pride in the achievement. He stated, 'Being recognized among the top workplaces in technology across the GCC is an honour that validates our belief that a strong company culture is a catalyst for sustainable growth. Our team is at the heart of everything we do, and this recognition is a reflection of their passion, dedication, and the values we live by every day.' The company revealed that this recognition comes during a phase of strategic expansion. It also highlights AmiViz's ability to scale while maintaining its core values. AmiViz continues to strengthen its position in cybersecurity distribution across the region. The company emphasized that its workplace culture plays a key role in this success. This announcement sends a clear message to employees, partners, and stakeholders. AmiViz is not only a leader in cybersecurity solutions but also a company that values its people as its greatest asset.
Arabian Post
a day ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
